PFE trade ideas
Possible Pfizer Play AlertPfizer has had exponential growth over the past few months with delta variant and most recent omicron variant. Through these ideas we have seen billions of vaccines purchased by other countries and the United States. U.S just administered 500 million doses along with that the FDA just gave the green light to oral antiviral pill. We see a double touch and fall leading to a big jump after a consolidation period in the end of November to early December and right now we are sitting in that exact same bout again and all these purchases of vaccines and antiviral pills being released. Its prominent that Pfizer is bound to reach new highs especially within the early months of 2022. First few calls initiated at 60.3 and a load in the 61.55 zone as we break resistance lines.
Stikes: January 28 2022-63 dollar calls- 20% chance of profit- Greeks showing decline of .03 a day with a delta of roughly .3 off the dollar jump
LevelsJust working on spotting levels as apposed to plays.
Weekly: Solid
Daily: Dotted
Hourly: Dashed
PFE: Don't believe the HypePFE is overrated and pumped by the media and those with agendas. I am expecting PFE to pullback to Target 1 55.66 - 55.47 and possibly down to Target 2 of 52.85 - 56.60.
PFE to the DownsideThere is so much baked into the markets with vaccines. I expect PFE to have some downside to 55.66 to 55.47 as a T1 downside Target.
Pfizer authorizes $1 billion for ORAL COVID-19 treatmentAn ORAL treatment for COVID would have to be one of those holy grail type products where literally everyone in the world needs it and probably on an annual basis...
It is probably years away but will no doubt get fast tracked when it is close to ready.
Big resistance area on a long term chart, but the world has changed in the last 2 years.
Feels expensive on the daily, but interesting to keep an eye on for sure.
Pretty big pullback on Pfizer. Will it recover?I find it quite interesting how these vaccine stocks (pretty much all of the Covid ones) have taken such a big hit on the concern about how effective any boosters might be.
Most governments globally on behalf of their citizens are trying to bulk purchase as many doses as they can and there is simply not enough supply.
I'd expect to see a recovery, but the main bit of news I want to keep an eye out for is the first one out of say Moderna and Pfizer who creates an oral booster type tablet.
Worth a look.
PFE: Continuation on ATHPFE: continuation off of ATHs based on promising FDA approvals and current pipeline. PFE is finding healthy price discovery. Cup and Handle formation observed on the monthly. 3Bar play observed on multiple intraday timeframes and on the daily. PTs of 62 issued recently // ATR: 2.06, Beta: 0.67
Long term patterns suggest PFE bulls still in play?Weekly chart on top shows long term cup and handle just filled recently near $46
while daily chart below shows there's also a trend continuation pattern.
With RSI rounding down, on short term, 50-53 seems like possible downside, with higher chances of trend resuming to upside and go beyond current 52-week highs!
Stop loss below 50, and use trailing stops as and if price advances higher!
$PFE keep an eye on it.$PFE has been trending up for the past few weeks. mostly probably because of the covid variant and news. today it just reach the ATH and could possibly continues when they release a news for oral medication for covid.
average move of this stock is about .70 to $2.00 depending on a day.
on a smaller time frame, the momentum is almost reaching the exhaustion.
possible Put play tomorrow as people take profits after reaching all time high.
Hello Guys,
welcome to this free and technical analysis. ( mostly momentum play )
I am going to explain where I think this stock is going to go over the next day or week play and where I would look for trading opportunities.
If you have any questions or suggestions which stock I should analyze, please leave a comment below.
If you enjoyed this analysis, I would definitely appreciate it, if you smash that LIKE button and maybe consider following my channel.
Thank you for watching and stay tune.
PFIZER - SELL strategyPFIZER shares even though in a long-term uptrend, may have some minor correction short-term.
The $ 58.61 resistance and $ 50.98 is the defined range currently, and selling into slightly higher levels is advisable.
RANGE TRADE $51-59 for now. For medium-term buy low $51 for move towards $ 78.
Pfizer outlook 2022phizer call options looking like a nice swing play for 2022 and with all the new covid variant talk i am sure there will be multiple catalyst to propel this company's price higher next year.
Pfe soon breakout to 60$? 3rd times a charm? keeps testing that resistance all day today. Nothing but good news coming down the tail pipe for catalyst ..
Entry over 56$.
stop loss 55.50
target 60$
LongPopular stock at the moment. The demand for medical products will still be stably high. Price is breaking through another resistance. Expect higher targets: first 60, 62
❤️ If you find this helpful and want more FREE forecasts in TradingView
. . . . . Please show your support back,
. . . . . . . . Hit the 👍 LIKE button,
. . . . . . . . . . . Drop some feedback below in the comment!
❤️ Your Support is very much 🙏 appreciated!❤️
💎 Want us to help you become a better Stock trader?
Now, It's your turn!
Be sure to leave a comment let us know how do you see this opportunity and forecast.
PFE candlestick analysis PFE stock prices test recent NOV 29 high. volume indicates Trend exauhstion. beware bulls!
PFE LONG Pfizer (PFE) said Monday it has agreed to acquire Arena Pharmaceuticals for $100 per share in an all-cash deal with an equity value of about $6.7 billion.
Arena shares soared by nearly 93% in premarket trading to $96.29.
PFE's RSI is almost at 70.0 the highest it has been in a long time. I'm expecting a new ATH,
$PFE with the breakout Very similar to AMD and MSFT charts, PFE is starting to breakout after 20+ years. I'm starting a position with intent to add going forward. 6-12 months i'm targeting $80-85 area.
$PFE with a Bullish outlook following its earnings #Stocks The PEAD projected a Bullish outlook for $PFE after a Positive over reaction following its earnings release placing the stock in drift B with an expected accuracy of 66.67%.
If you would like to see the Drift for another stock please message us. Also click on the Like Button if this was useful and follow us or join us.
Pfizer | Fundamental Analysis | LONG SETUP | MUST READ 🔔Some people say that the Chinese word for "crisis" is composed of two characters, one meaning "danger" and the other meaning "opportunity. In fact, this is not the case. Nevertheless, the word often hits the mark. While many crises carry danger, they also often present opportunities.
In the case of COVID-19, we can certainly see this happening. To date, more than 5 million people worldwide have died from this viral infection. At the same time, numerous businesses made a lot of money during the pandemic by selling personal protective equipment, tests, therapies, and vaccines.
None of them benefited more financially than Pfizer. In the third quarter alone, the company reported $13 billion in sales of its COVID-19 Comirnaty vaccine. SVB Leerink analyst Jeffrey Porges estimates that Pfizer expects to make a staggering $131 billion on sales of the COVID-19 vaccine by the end of next year. But is this pharmaceutical company stock worth buying?
Let's first look at how Pfizer could make $160 billion on coronavirus over the next two years. First, we need to consider the company's projected revenue of $36 billion in 2021 from Comirnaty.
Porges believes that sales of the vaccine will actually be much higher this year. He expects that approvals and authorizations in many countries for booster doses and for children could boost Comirnaty's total worldwide sales to $59 billion in 2021.
The Wall Street analyst expects vaccine sales to drop to about $48 billion next year. So by the end of 2022, Pfizer's revenue from Comirnaty sales will be $107 billion.
But Comirnaty probably won't be Pfizer's only source of revenue from COVID-19. The company hopes to soon get emergency approval and approval for the oral antiviral drug Paxlovid in the U.S. and other countries.
Purges predicts that sales of Pfizer's COVID-19 pills could be about $95 million this year and $24 billion next year. If you add it all up, Pfizer's total revenue from COVID-19 sales would be about $131 billion over two years.
Pfizer shares the profits from the sale of Comirnaty with its partner BioNTech. Although the company's revenue will be huge, its profits from the vaccine will not be as large.
Sales of the COVID-19 vaccine are also likely to be lower in 2023. Porges, however, predicts that Paxlovid sales will grow to $33 billion in 2023. After 2023, though, the picture becomes less cheerful.
Many investors speculate that COVID-19 will be like the flu, requiring annual vaccinations. But it is too early to judge whether this will actually be the case. If not, Pfizer's revenues will fall markedly over the next few years.
Looking ahead, Pfizer faces a patent cliff beginning in 2026. Several of the company's currently best-selling drugs will lose patent exclusivity in the second half of this decade.
Despite these potential problems, it should be noted that there are three reasons why Pfizer stock is still worth buying.
Let's start with the most compelling one on the list, the dividend. Currently, Pfizer's dividend yields just under 3%. Given the cash flow the company will generate, there is a good chance that the dividend will increase.
Pfizer is also predicted to use its growing cash reserves to make business development deals. The company is expected to license more promising drugs developed by other drugmakers. In addition, many believe that Pfizer will make a major acquisition in the not-too-distant future. The right deals could go a long way toward offsetting the impact of the patent cliff, which is looming in a few years.
Finally, there is the possibility that sales of Comirnaty (or its successors) and Paxlovid will remain strong for a long time to come. COVID-19 could become endemic and bring Pfizer much more money over the next decade than anyone expects.
Given that Pfizer made $13 billion on sales of its coronavirus vaccine in the third quarter alone, it's understandable why investors are wary of the rapidly evolving threat posed by the new variant, dubbed Omicron. If Omicron proves to be as insidious as early reports suggest, it could well become a serious problem for vaccinated people and vaccine manufacturers worldwide.
But the fear of Pfizer's defeat of Omicron is quite premature. In fact, there is probably no company in a better position to solve such a problem as a new option, as an opportunity to rise to the next level.
The dangers of this crisis may not go away. And the opportunities for Pfizer may not disappear either.
U PFEUnitySoftware PFE Some follow-up and cleanup of these two markets. Sometimes I go back and look to see actually did reverse, and how far it moved. On equity markets (which I never trade) I sometimes fail to go back to evaluate and critique. I critique all my trades...and summerize it.
